Schottenfeld D, Nash A G, Robbins G F, Beattie E J
Cancer. 1976 Aug;38(2):1001-7. doi: 10.1002/1097-0142(197608)38:2<1001::aid-cncr2820380252>3.0.co;2-5.
After all records of patients with breast cancer who received primary treatment at Memorial Hospital in 1960 were reviewed, 304 women with operable, infiltrating carcinoma were identified and classified clinically according to the TNM system of the American Joint Committee for Cancer Staging and End Results Reporting. There were 66 patients (22%) classified under Stage I, 176 (58%) under Stage II, and 62 (20%) under Stage III. There were 82 patients (27%) in whom the nodal status was misclassified clinically. The observed 10-year survival was 59.7%. The 10-year end results (with 95% confidence limits) diminished significantly in relation to advancing clinical stage of disease--90.9% (+/-6.9%) for Stage I, 57.1% (+/-7.3%) for Stage II, and 33.9% (+/-11.8%) for Stage III patients. The 10-year survival in patients with pathologically negative axillary nodes was 71.5%, and in the patients with pathologically positive axillary nodes, 48.3%.
在对1960年在纪念医院接受初次治疗的所有乳腺癌患者记录进行审查后，确定了304例患有可手术浸润性癌的女性，并根据美国癌症分期和最终结果报告联合委员会的TNM系统进行了临床分类。其中66例（22%）归为I期，176例（58%）归为II期，62例（20%）归为III期。有82例（27%）患者的淋巴结状态临床分类错误。观察到的10年生存率为59.7%。随着疾病临床分期的进展，10年最终结果（95%置信区间）显著降低——I期为90.9%（±6.9%），II期为57.1%（±7.3%），III期患者为33.9%（±11.8%）。腋窝淋巴结病理检查阴性的患者10年生存率为71.5%，腋窝淋巴结病理检查阳性的患者为48.3%。
